Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-122

Response rate (tumour shrinkage) is an only proxy for what actually matters - survival time. When you have OS data you really should be presenting that and not RR data in the abstract.

A far bigger issue with the trial was the patients were not really randomised and the bisantrene arm contained far more advanced and difficult to treat patients than the doxorubicin arm. This is why when they corrected for this the HR slightly favoured bisantrene on OS.

Yes the trial showed that mitoxantrone was not useful in breast cancer. I know this from speaking to the old guys was extremely disappointing for Lederle as mitoxantrone was their golden child having dropped bisantrene.